These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32125938)

  • 21. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Deapen D; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2020 Apr; 6(4):e196400. PubMed ID: 32027353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
    Lovejoy LA; Rummel SK; Turner CE; Shriver CD; Ellsworth RE
    Fam Cancer; 2021 Jul; 20(3):181-187. PubMed ID: 33083949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
    BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
    Rowlands CF; Allen S; Balmaña J; Domchek SM; Evans DG; Hanson H; Hoogerbrugge N; James PA; Nathanson KL; Robson M; Tischkowitz M; Foulkes WD; Turnbull C
    Ann Oncol; 2024 Oct; 35(10):892-901. PubMed ID: 38986768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).
    Kleiblová P; Novotný J; Cibula D; Curtisová V; Dubová O; Foretová L; Germanová A; Janatová M; Havránek O; Hojsáková M; Hudcová M; Koudová M; Krutílková V; Palacova M; Paulich S; Petrakova K; Presl J; Puchmajerová A; Soukupová J; Šenkeříková M; Šimková Z; Štěpánková H; Šubrt I; Tachecí I; Tesner P; Urban O; Veselá K; Vilímová Š; Vlčková Z; Vočka M; Weinberger V; Zikán M; Zimovjanová M; Kleibl Z
    Klin Onkol; 2024; 38(4):292-299. PubMed ID: 39174333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
    Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.
    Davidson AL; Michailidou K; Parsons MT; Fortuno C; Bolla MK; Wang Q; Dennis J; Naven M; Abubakar M; Ahearn TU; Alonso MR; Andrulis IL; Antoniou AC; Auvinen P; Behrens S; Bermisheva MA; Bogdanova NV; Bojesen SE; Brüning T; Byers HJ; Camp NJ; Campbell A; Castelao JE; Cessna MH; Chang-Claude J; Chanock SJ; Chenevix-Trench G; ; Collée JM; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Glendon G; González-Neira A; Grassmann F; Gronwald J; Guénel P; Hadjisavvas A; Haeberle L; Hall P; Hamann U; Hartman M; Ho PJ; Hooning MJ; Hoppe R; Howell A; ; Jakubowska A; Khusnutdinova EK; Kristensen VN; Li J; Lim J; Lindblom A; Liu J; Lophatananon A; Mannermaa A; Mavroudis DA; Mensenkamp AR; Milne RL; Muir KR; Newman WG; Obi N; Panayiotidis MI; Park SK; Park-Simon TW; Peterlongo P; Radice P; Rashid MU; Rhenius V; Saloustros E; Sawyer EJ; Schmidt MK; Seibold P; Shah M; Southey MC; Teo SH; Tomlinson I; Torres D; Truong T; van de Beek I; van der Hout AH; Wendt CC; Dunning AM; Pharoah PDP; Devilee P; Easton DF; James PA; Spurdle AB
    Am J Hum Genet; 2024 Sep; 111(9):2059-2069. PubMed ID: 39096911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
    Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
    Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.
    Rezoug Z; Totten SP; Szlachtycz D; Atayan A; Mohler K; Albert S; Feng L; Lemieux Anglin B; Shen Z; Jimenez D; Hamel N; Meti N; Esfahani K; Boileau JF; Prakash I; Basik M; Meterissian S; Tremblay F; Fleiszer D; Anderson D; Chong G; Wong SM; Foulkes WD
    JAMA Netw Open; 2024 Sep; 7(9):e2431427. PubMed ID: 39226054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
    Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.